Business Wire

Aura Biosciences Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights | Business Wire

Aura plans to select the route of administration and treatment regimen to initiate the pivotal program in Q4 of 2022. Multiple clinical studies of belzupacap sarotalocan were presented at the ...
Seeking Alpha

Aura Announces 2022 Annual Financial and Operational Results and 2023 Guidance

ROAD TOWN, British Virgin Islands, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Aura Minerals Inc. (ORA:CA) (B3: AURA33) (OTCQX: ORAAF) (“Aura” or the “Company”) announces that it has filed its audited ...
Nasdaq

Aura Biosciences to Present Preclinical Data Highlighting AU‑011’s Potential to Target a Broad Number of Tumor Types at the 2022 AACR Annual Meeting

Aura Biosciences, Inc. (NASDAQ: AURA) is a clinical-stage biotechnology company developing virus-like drug conjugates (VDCs), a novel class of therapies, for the treatment of multiple oncology ...
Nasdaq

Aura Minerals Releases 2022 Sustainability Report

62% reduction in the frequency rate of accidents with absences. 92% recycling of water across all our operations. Consolidation of the eight material topics of Aura, based on input from internal and ...
Digital Journal

Aura Changes Record and Payment Dates for Dividend to be paid in December 2022

ROAD TOWN, British Virgin Islands, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Aura Minerals Inc. (TSX: ORA, B3: AURA33 and OTCQX: ORAAF) (“Aura” or the “Company”) announced that, further to the Company’s press ...
Business Wire

Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

BOSTON--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology ...